Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Audentes Therapeutics Inc. (BOLD)

59.97   0 (0%) 01-14 16:00
Open: 59.98 Pre. Close: 59.97
High: 59.99 Low: 59.97
Volume: 2,080,290 Market Cap: 2,750M
Audentes Therapeutics Inc is a biotechnology company. It is engaged in developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 60.11 - 60.406 60.406 - 60.646
Low: 59.13 - 59.543 59.543 - 59.878
Close: 59.398 - 60.016 60.016 - 60.518

Technical analysis

as of: 2020-02-14 4:27:03 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 70.08     One year: 81.85
Support: Support1: 59.55    Support2: 59.27
Resistance: Resistance1: 60.00    Resistance2: 70.08
Pivot: 59.92
Moving Average: MA(5): 59.97     MA(20): 59.84
MA(100): 38.31     MA(250):
MACD: MACD(12,26): 2.85     Signal(9): 3.81
Stochastic oscillator: %K(14,3): 94.32     %D(3): 94.79
RSI: RSI(14): 88.53
52-week: High: 60.00  Low: 22.97  Change(%): 141.8
Average Vol(K): 3-Month: 133537  10-Days: 108009

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
BOLD has closed below upper band by 32.6%. Bollinger Bands are 97% narrower than normal. The narrow width of the bands suggests low volatility as compared to BOLD's normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Thu, 04 Jun 2020
Jun 04, 2020 - Opaleye Management Inc. Buys Protara Therapeutics Inc, Eton Pharmaceuticals Inc, Kala Pharmaceuticals Inc, Sells Epizyme Inc, Turning Point Therapeutics Inc, Audentes Therapeutics Inc - GuruFocus.com

Fri, 15 May 2020
May 15, 2020 - Casdin Capital, LLC Buys Blueprint Medicines Corp, Twist Bioscience Corp, Gilead Sciences Inc, Sells Audentes Therapeutics Inc, Illumina Inc, Deciphera Pharmaceuticals Inc - GuruFocus.com

Mon, 02 Dec 2019
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics - Business Wire

Mon, 11 Nov 2019
Audentes Therapeutics, Inc. (BOLD) Q3 2019 Earnings Call Transcript - The Motley Fool

Sun, 12 Jan 2020
2019 Review: Most Favored Hedge Fund Stocks vs. Audentes Therapeutics, Inc. (BOLD) - Yahoo Finance

Fri, 04 Oct 2019
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange: 
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 46
Shares Float (M) 37
% Held by Insiders 7.30
% Held by Institutions 100.14
Shares Short (K) 2,090
Shares Short P. Month (K)

Stock Financials

EPS -3.990
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 8.380
Profit Margin
Operating Margin
Return on Assets (ttm) -28.4
Return on Equity (ttm) -50.6
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -3.702
Qtrly Earnings Growth
Operating Cash Flow (M) -147
Levered Free Cash Flow (M) -88

Stock Valuations

PE Ratio -15.03
PEG Ratio -1.09
Price to Book value 7.16
Price to Sales
Price to Cash Flow -18.66

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.